Financière de Tubize SA (EBR:TUB)

Market Cap	9.25B +68.7%
Revenue (ttm)	n/a
Net Income	93.23M +3.5%
EPS	2.09 +3.5%
Shares Out	44.51M
PE Ratio	99.22
Forward PE	n/a
Dividend	1.08 (0.53%)
Ex-Dividend Date	May 7, 2026

Volume	9,336
Average Volume	20,872
Open	208.60
Previous Close	207.80
Day's Range	207.00 - 209.20
52-Week Range	120.00 - 250.50
Beta	0.37
RSI	52.93
Earnings Date	Mar 21, 2026

About Financière de Tubize

Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1928
• Country: Belgium
• Stock Exchange: Euronext Brussels
• Ticker Symbol: TUB